Lodotra™

Partner: Nitec Pharma

Geoclock™ delivers a chrono-therapeutic approach to helping patients with rheumatoid arthritis by reducing early morning stiffness and pain.

Lodotra™, developed for Nitec Pharma, is a novel modified-release formulation of prednisone, a widely used anti-inflammatory drug for treating the pain and stiffness caused by rheumatoid arthritis.

Using SkyePharma’s Geoclock™ drug delivery system, prednisone is rapidly released from the tablet core about 4 hours after ingestion. This means that Lodotra™ can be conveniently taken at bedtime, and prednisone is released in the early hours of the morning. This allows inhibition of pro-inflammatory cytokine levels when they are at their peak while the patient is sleeping, resulting in significantly less early morning stiffness of the joints.

Lodotra™ has successfully completed Phase III development in Europe in 2006. Nitec has filed for marketing approval in 15 European countries. Development is ongoing in the US.

For further information about Lodotra™, see Nitec Pharma.

SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom

Lodotra